AL amyloidosis of the mesentery is rare and it has been associated with an extremely poor prognosis. We herein report a case of AL amyloidosis with diffuse calcifications (>13 cm) throughout the mesentery. After treatment with daratumumab, bortezomib, and dexamethasone, the patient achieved a very good partial response (VGPR). However, even after continuing the treatment for over 14 months while maintaining VGPR and achieving a kidney organ response, diffuse calcifications remained throughout the mesentery. Although rare, AL amyloidosis should be considered in the differential diagnosis of mesenteric calcification.
Furukawa et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: